In vitro forecasting of drugs which may interfere with the biotransformation of midazolam
- 1 December 1991
- journal article
- case report
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 41 (6), 573-578
- https://doi.org/10.1007/bf00314987
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Pharmacokinetics of Midazolam Following Intravenous and Oral Administration in Patients with Chronic Liver Disease and in Healthy SubjectsThe Journal of Clinical Pharmacology, 1989
- The P450 Superfamily: Updated Listing of All Genes and Recommended Nomenclature for the Chromosomal LociDNA, 1989
- No Evidence of a Genetic Polymorphism in the Oxidative Metabolism of MidazolamClinical Pharmacokinetics, 1988
- Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liverBiochemical Pharmacology, 1988
- Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidationBiochemical Pharmacology, 1987
- Midazolam in intensive care.BMJ, 1984
- Accumulation of midazolam in patients receiving mechanical ventilationBMJ, 1984
- Accumulation of midazolam after repeated dosage in patients receiving mechanical ventilation in an intensive care unit.BMJ, 1984
- Effect of Age, Gender, and Obesity on Midazolam KineticsAnesthesiology, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984